Annals of internal medicine

Weekly and Biweekly Bofanglutide Compared to Semaglutide in Chinese Patients with Type 2 Diabetes

Updated

Abstract

Bofanglutide is a novel glucagon-like peptide-1 receptor agonist under development for type 2 diabetes mellitus (T2DM) and overweight and obesity.

  • Bofanglutide may help regulate blood sugar levels in individuals with T2DM.
  • This medication could assist in weight management for people with obesity.
  • It is associated with the potential for improved metabolic health in overweight individuals.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Disclosures: Disclosure forms are available with the article online.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free